Electra Therapeutics, Inc. (NasdaqGS: ETRA)
Health Care · Biotechnology · US
$8.84
-2.96% today · -33.3% 1Y
Public summary
A free snapshot of Electra Therapeutics, Inc., with figures as of Nov 15, 2026. The full analysis is in the app.Open in the app Electra Therapeutics, Inc. (NasdaqGS: ETRA) operates in the Biotechnology industry within the Health Care sector. The company is valued at $554.86M and employs 46 people.
Over the last twelve months the share price has lost 33.3%, trading between 7.31 and 15.50.
Tweenvest scores Electra Therapeutics, Inc. across four factors: quality 44/100, value 100/100. Its strongest factor is value.
ETRA price history
Key figures
- Market cap
- $554.86M
- Revenue (TTM)
- —
- P/E
- -22.39
- EPS
- -1,408.52
- Dividend yield
- —
- Beta (5Y)
- —
- 52-week high
- $15.50
- 52-week low
- $7.31
- Avg volume (3M)
- —
- Shares outstanding
- 62.77M
- Employees
- 46
- Next earnings
- —
About Electra Therapeutics, Inc.
Electra Therapeutics, Inc. is a clinical stage biotechnology company. It is engaged in therapies against novel targets for diseases in immunology and cancer. The company was founded by Adam Rosenthal on October 11, 2018 and is headquartered in South San Francisco, CA.
- ISIN
- US2848251060
- Founded
- 2018
- Listed since
- Sep 18, 2026
- Exchange
- Nasdaq Global Select
- Currency
- USD
Other Biotechnology companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| Abbisko Medicine Co., Ltd.SEHK: 2256 | $573.25M | HK$6.79 | -5.69% |
| Entera Bio Ltd.NasdaqCM: ENTX | $567.69M | $3.26 | +8.67% |
| Steminent Biotherapeutics Inc.TPEX: 7729 | $564.30M | NT$230.50 | -0.86% |
| Adlai Nortye Group Ltd.NasdaqGM: ANL | $562.84M | $8.74 | -7.81% |
| Climb Bio, Inc.NasdaqGM: CLYM | $546.27M | $9.30 | -4.91% |
| Myriad Genetics, Inc.NasdaqGS: MYGN | $542.92M | $5.66 | -0.35% |
| REGENXBIO Inc.NasdaqGS: RGNX | $530.96M | $8.03 | -5.19% |
| TaiMed Biologics Inc.TPEX: 4147 | $527.92M | NT$63.70 | +1.27% |